Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | MIF | P14174 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30331216 | 1.00 | ADRB1 (0.52) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL24682880 | 0.85 | HTR2A (0.42) | ADRA1AHTR2AHTR2BADRA2CDRD3 | |
| SCHEMBL21291430 | 0.82 | ADRB1 (0.58) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL5011905 | 0.79 | LMNA (0.46) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL16002846 | 0.79 | PTPN5 (0.42) | HTR2AHTR2BTSHRLMNAKDM4E | |
| SCHEMBL7122627 | 0.78 | ADRB1 (0.48) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL21739802 | 0.78 | HDAC4 (0.42) | HTR2AHTR2BACHE | |
| SCHEMBL51528 | 0.76 | ADRB1 (0.61) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL921895 | 0.76 | ADRB1 (0.61) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL11619117 | 0.76 | ADRB1 (0.61) | ADRB1ADRA1AMIFHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-4116291-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCERS AND INFLAMMATIONS | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-01-11 | — | — | EP | disclosed |
| EP-4116291-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCERS AND INFLAMMATIONS | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-01-11 | — | — | EP | disclosed |
| CN-113354585-A | Synthesis of novel EP4 antagonists and their use in cancer and inflammation | 湖北生物医药产业技术研究院有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-102137851-B | Compound as vanilloid receptor antagonist, isomer thereof or pharmaceutically acceptable salt thereof, and pharmaceutical composition comprising same | AMOREPACIFIC CORP | 2014-08-27 | — | — | CN | disclosed |
| EP-2307394-B1 | SULPHONAMIDES AS VANILLOID RECEPTOR ANTAGONIST | AMOREPACIFIC CORP (KR) | 2012-09-26 | — | — | EP | disclosed |
| CN-102137851-A | Novel compounds as vanilloid receptor antagonists, isomers thereof or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the same | AMOREPACIFIC CORP | 2011-07-27 | — | — | CN | disclosed |
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2011-06-23 | — | — | US | disclosed |
| EP-2307394-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010002209-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | ADRB1 244/4885ADRA1A 376/4885MIF 1579/4885 |
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | PTGER4, PTGER3, PTGER2 | ADRB1 109/4885ADRA1A 509/4885MIF 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.